Brief: Monopar Therapeutics QTRLY Net Loss $0.14 Per Share
09/11/2023 12:32
Nov 9 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL
RESULTS AND RECENT DEVELOPMENTS
* MONOPAR THERAPEUTICS INC: QTRLY NET LOSS $0.14 PER SHARE
* MONOPAR THERAPEUTICS INC: CASH, CASH EQUIVALENTS AND
SHORT-TERM
INVESTMENTS AS OF SEPTEMBER 30, 2023 WERE $8.5 MILLION
Source text for Eikon: ID:nGNX5Wq2gF
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla